1 min read
Add as a preferred source on GoogleJohnson & Johnson's JNJ-6143 Shows 75% Response Rate in Early Trial
The oral RIPTAC small molecule was previously known as HLD-0915.
Johnson & Johnson said its experimental oral drug JNJ-6143 produced a 75% tumor response rate in an early-stage trial involving people with advanced prostate cancer.
JNJ-6143 is a small molecule in the Regulated Induced Proximity Targeting Chimera (RIPTAC) class. The compound was previously known as HLD-0915.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.